Comorbid Chronic Lung Disease on Heart Failure
Conditions
Brief summary
Comorbid chronic lung disease (CLD) increases mortality in heart failure (HF) patients. Understanding the predictors and pathophysiology of HF can improve the efficacy of HF treatment. This study evaluated the cardiopulmonary exercise test (CPET) results to identify significant predictors on long-term outcomes in HF patients with CLD.
Detailed description
The CPET was administered in a cohort of 169 HF outpatients with exercise intolerance at a tertiary referral center between May 2007 and July 2010. A CLD was defined as abnormal spirometry accompanied by clinical symptoms and signs included in the Global Initiative for Chronic Obstructive Lung Disease criteria. The primary endpoint was defined as CV mortality or the first HF hospitalization. Totally 49 events occurred before the end of follow up in January 2018.
Interventions
DIAGNOSTIC_TESTcardiopulmonary exercise test
Patients performed an upright graded bicycle exercise using a personalized protocol or performed a motorized treadmill exercise using a modified Bruce protocol. Peak VO2 and peak respiratory exchange ratio (RER) were defined as the highest 30-second average value obtained during exercise. The anaerobic threshold (AT) was determined by V-slope method. The VE(minute ventilation)/VCO2 (carbon dioxide production) at AT was calculated as the average VE/VCO2 for 1 minute during AT and immediately after AT. If AT could not be determined, the lowest VE/VCO2 was determined by averaging the three lowest consecutive 0.5-minute data points.
Sponsors
Chang Gung Memorial Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* outpatients ≥ 18 years of age, male or female. * Patients with a diagnosis of heart failure with clinical symptoms and echocardiography evidence * Patients received cardiopulmonary exercise test exams
Exclusion criteria
* Cannot tolerance exercise test due to muscular-skeletal disorder * Cannot co-operate all functional studies * Family reject to participate in this project
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants That Had Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or First Heart Failure (HF) Hospitalization | May, 2007 ~ January, 2018 | Number of participants that had occurrence of the composite endpoint, which is defined as either CV death or first HF hospitalization |
Outcome results
None listed